USING PATIENT DERIVED ORTHOTOPIC XENOGRAFT MODELS AND A NOVEL IMMUNOCOMPETENT MODEL OF GBM, THE EFFICACY OF A MTl-MMP INHIBITOR IN COMBINATION WITH RADIATION/TMZ WILL BE TESTED TO DETERMINE ITS EFFECTS ON THE IMMUNE COMPONENT OF THE TUMOR MICROENVIRONMENT.

Pl: Barbara Bedogni, Ph.D.
Associate Professor, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery
University of Miami Miller School of Medicine

Close Menu